Project Grant HT94252510577
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$845K
Federal Agency
Defense Health Agency
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Durham, NC 27705, USA
Similar Awards
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
This $828,591 federal Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports Duke University's research efforts to target the tumor microenvironment and enhance immunotherapy for small cell lung cancer (SCLC). The award, effective May 1, 2025 through April 30, 2027, will enable Duke to conduct advanced biomedical research focused on developing innovative solutions to improve treatment outcomes for this challenging...
This $241,500 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Duke University focused on "Understanding the Molecular Communication Between Prostate Cancer Cell Types". The award period runs from September 1, 2025 to August 31, 2027. As a leading research institution with expertise in medical research, Duke University will utilize this funding to conduct advanced scientific...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
The Defense Health Agency has awarded a $1,581,751 Project Grant to Duke University to conduct the "THERAPEUTIC INTERVENTION TO REVERSE GASTRIC PRECANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This federal grant, with a performance period from June 1, 2024 to May 31, 2028, will enable Duke University's researchers to investigate innovative therapeutic interventions to reverse precancerous gastric conditions. The Military Medical...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
This $724,500 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at Duke University to investigate "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer." The award, with a performance period from March 1, 2025 to February 29, 2028, will enable Duke University's researchers to explore innovative approaches to treating breast cancer, with a focus on addressing...